Covis Pharma is proposing to narrow the current indication for its preterm birth prevention drug Makena (hydroxyprogesterone caproate or 17-OHPC), limiting its use to high-risk patients while it conducts a new randomized, controlled trial in the US.
However, the US Food and Drug Administration's Center for Drug Evaluation and Research stands in opposition, saying the drug should...